NCT06876402Completed
Gene Molecular Alterations as Disease Prognostic Markers in Patients With Non-small Cell Lung Cancer (NSCLC)
Assessment of the Prevalence and Prognostic Value of Gene Molecular Alterations and Association With Clinicopathological Factors in Patients With Non-small Cell Lung Cancer (NSCLC)
Source: ClinicalTrials.gov · Last updated 14 Oct 2026
Brief summary (registry, in English)
GEMA-proN is an observational, multicenter, single cohort, retrospective clinical trial. The aim of the trial is to assess the prevalence, and prognostic value of genetic molecular alterations and investigate correlations with clinicopathological features in unselected patients with histologically confirmed non-small cell lung cancer (NSCLC).
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 367 (actual)
- First submitted
- 10 Mar 2025
- Start date
- 9 Sept 2013
- Primary completion date
- 13 Oct 2024
- Lead sponsor
- Hellenic Cooperative Oncology Group
- Diseases
- Lung cancer
- NCT number
- NCT06876402
What you commit to
- Study type: Observational
- Participants enrolled: 367
- From 9 Sept 2013 to the primary completion date, 13 Oct 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- \- Patients with personal medical history of malignancy, other than non-small cell lung cancer (NSCLC), with the exclusion of completely resected non-melanoma skin cancers, in situ carcinomas of the cervix uteri, in situ bladder carcinomas, in situ ductal breast carcinoma, and other cancers treated with curative intent with no evidence of disease recurrence for 5 years.
Who the study is looking for
- Age 18 and above.
- Histologically confirmed non-small cell lung cancer (NSCLC).
- Adequate, and suitable tissue for the testing of somatic genetic alterations.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hellenic Cooperative Oncology Group (HeCOG) Coordinator of this site? Confirm its status | Athens | Greece | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.